Novel FGL2::PDGFD and TGFBI::PDGFB Fusions Expand the Molecular Spectrum of Dermatofibrosarcoma Protuberans
Genes, Chromosomes and Cancer · 2026
DOI: 10.1002/gcc.70110 ↗Kurz gefasst
Fallbericht in der Zeitschrift Genes, Chromosomes and Cancer, 2026. Verfasst von Jeffrey M Cloutier und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA. Hauptthemen laut MEDLINE: Dermatofibrosarcoma, Extracellular Matrix Proteins, Fibrinogen, Lymphokines. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Dermatofibrosarcoma protuberans (DFSP) is a locally aggressive fibroblastic neoplasm characterized by recurrent COL1A1::PDGFB fusions that drive autocrine PDGFR‐β activation. Recent sequencing studies have revealed rare DFSPs with alternative noncanonical PDGFB or PDGFD rearrangements, underscoring the genetic diversity of PDGF‐ligand activation in this tumor. Here, we describe two conventional DFSPs harboring previously unreported fusions: FGL2::PDGFD and TGFBI::PDGFB . In the first case, FGL2(ex1)::PDGFD(ex6) replaces the PDGFD N‐terminal CUB domain with the FGL2 signal peptide, a configuration predicted to generate a constitutively active, secreted PDGFD ligand. In the second case, TGFBI(ex14)::PDGFB(ex3) juxtaposes PDGFB to the highly expressed extracellular matrix gene TGFBI , providing an alternative promoter context for PDGFB overexpression. Both cases showed classic DFSP morphology and diffuse CD34 expression. These findings expand the molecular landscape of DFSP and illustrate convergent mechanisms of PDGFR‐β activation achieved through diverse yet functionally equivalent genomic rearrangements.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Clinical Genomics Department, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.
- Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
- Department of Cellular Pathology, University Hospitals Birmingham, Birmingham, UK.
ORCID-Profile: Jeffrey M Cloutier, Carina A Dehner, Cyril Fisher, Khin Thway, Konstantinos Linos
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Cloutier, J. M., Yakoub, M. A., Hameed, M., Cavalchini, S., Dehner, C. A., Fisher, C., Thway, K., & Linos, K. (2026). Novel FGL2::PDGFD and TGFBI::PDGFB Fusions Expand the Molecular Spectrum of Dermatofibrosarcoma Protuberans. Genes, Chromosomes and Cancer. https://doi.org/10.1002/gcc.70110
Vancouver
Cloutier JM, Yakoub MA, Hameed M, Cavalchini S, Dehner CA, Fisher C, et al. Novel FGL2::PDGFD and TGFBI::PDGFB Fusions Expand the Molecular Spectrum of Dermatofibrosarcoma Protuberans. Genes, Chromosomes and Cancer. 2026. doi:10.1002/gcc.70110
BibTeX
@article{Cloutier2026,
author = {Cloutier, Jeffrey M and Yakoub, Mohamed A and Hameed, Meera and Cavalchini, Silvia and Dehner, Carina A and Fisher, Cyril and Thway, Khin and Linos, Konstantinos},
title = {Novel FGL2::PDGFD and TGFBI::PDGFB Fusions Expand the Molecular Spectrum of Dermatofibrosarcoma Protuberans},
journal = {Genes, Chromosomes and Cancer},
year = {2026},
doi = {10.1002/gcc.70110}
}
EUVIMED